Bryan Johnson, the technology entrepreneur and public face of the “Don’t Die” movement, says filters, retouching and lighting may be the most effective ways to look younger—even after spending millions of dollars on efforts to slow or reverse aging.
Johnson made the comment in a post on X on October 6. The remark stood out because it came from someone who has said he spends about $2 million a year attempting to make his body function more like that of an 18-year-old. His highly intensive program has included major lifestyle changes, medical monitoring and experimental treatments.
The post does not mean Johnson has abandoned longevity research. Instead, it reflects a shift in emphasis that followed several health developments involving him and his partner, Kate Tolo.
A summer of medical diagnoses and experimentation
Johnson disclosed on June 30 that he had been diagnosed with autoimmune gastritis in May. The chronic condition occurs when the immune system attacks the lining of the stomach.
Tolo, who is also a co-founder of Johnson’s Blueprint health company, was later diagnosed with endometriosis, PMOS and adenomyosis after around six weeks of testing. The diagnoses appear to have helped push women’s health higher on Johnson’s agenda. Tolo told Australia’s ABC that female health had always been a future priority and said she aims to become the “world’s most measured woman.” Her health protocol gathers 14 million data points on her menstrual cycle.
Johnson also drew attention in July when he described a laboratory project as having “cloned” him as a newborn. A community note attached to the post disputed that description. The material created was induced pluripotent stem cells, which are adult cells reprogrammed into a stem-cell-like state, rather than a genetic clone.
Johnson said the cells could potentially be used to test therapies, grow organs for transplantation, develop treatments and create a source of young cells. He described the laboratory-grown material as a “baby-Bryan” in a petri dish.
From extending life to curing disease
The broader change came in a July 24 post, when Johnson said he had nearly closed his longevity company the previous year. He said he had been considering what to build as artificial intelligence approaches what he called “superintelligence.” His answer was a focus on curing diseases.
Johnson said he had redirected Immortals, a program launched in February at a cost of $1 million a year, toward building tools that allow individuals to identify and address their own health problems. The program initially had three places. Johnson and Tolo are its first customers.
The program’s existing areas of focus remain in place, including nutrition, GLP-1 drugs, hormones, peptides and biomarkers. It has also added stem cells, organoids and the development of personalized therapies. An organoid is a small, laboratory-grown model of tissue or an organ that can be used in research.
Johnson cited other cases while explaining the new direction. He referred to GitLab co-founder Sid Sijbrandij, who reported no evidence of disease after taking an intensive approach to his cancer, and to Sydney engineer Paul Conyngham, whose custom mRNA vaccine reportedly reduced his dog’s tumors by about 75%. Those examples were presented by Johnson as part of his reasoning for concentrating on disease treatment.
According to Decrypt, Johnson has continued to describe his physical condition in unusually ambitious terms. Last month, he wrote that he was “in many ways” 18, pointing to sleep, fertility, resting heart rate, vascular health and inflammation as areas he said were comparable to those of a teenager.
He also identified exceptions: hearing and somatic mutations. Somatic mutations are genetic changes that occur in body cells during a person’s life. Johnson additionally acknowledged that he looks 49, his actual age—an observation that helps explain his latest comment about cosmetic tools such as filters, retouching and lighting.
The 2039 immortality target remains
Despite the change in focus, Johnson has not withdrawn his long-term ambition. He told ABC that he remains committed to reaching immortality by 2039, while acknowledging that this is no longer his only goal. The target is 13 years away and would place him in his 60s if reached.
The distinction is important: Johnson’s recent statements combine an ongoing interest in radically extending life with a more immediate focus on diagnosing and treating disease. His latest post concerns appearance rather than a claim that cosmetic techniques can change underlying biological age.
Market picture
Moneyiar market data at the stated times showed a mixed but mostly weaker picture among the tracked digital assets on October 7:
- Filecoin (FIL) was priced at $1.0642584089, down 9.8% over 24 hours and 0.77% over seven days, as of 10:28 a.m. (+03:30).
- Plasma (XPL) traded at $0.087447069, down 5.37% in 24 hours and 9.78% over seven days, as of 10:29 a.m. (+03:30).
- Audiera (BEAT) was at $0.0966461527, up 28.94% over 24 hours but down 22.33% over seven days, according to data as of September 12 at 3:59 a.m. (+03:30).
- Four (FORM) stood at $0.2703604538, down 3.37% over 24 hours and 6.81% over seven days, as of 10:29 a.m. (+03:30).
